- Home
- TOYO vs VTYX Comparison
TOYO vs VTYX Comparison
Compare TOYO & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- VTYX
- Stock Information
- Founded
- TOYO 2022
- VTYX 2018
- Country
- TOYO Japan
- VTYX United States
- Employees
- TOYO 528
- VTYX N/A
- Industry
- TOYO
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- TOYO
- VTYX Health Care
- Exchange
- TOYO NYSE
- VTYX Nasdaq
- Market Cap
- TOYO 153.8M
- VTYX 154.9M
- IPO Year
- TOYO N/A
- VTYX 2021
- Fundamental
- Price
- TOYO $3.53
- VTYX $1.70
- Analyst Decision
- TOYO
- VTYX Buy
- Analyst Count
- TOYO 0
- VTYX 4
- Target Price
- TOYO N/A
- VTYX $11.33
- AVG Volume (30 Days)
- TOYO 18.9K
- VTYX 1.5M
- Earning Date
- TOYO 05-15-2025
- VTYX 05-08-2025
- Dividend Yield
- TOYO N/A
- VTYX N/A
- EPS Growth
- TOYO 350.49
- VTYX N/A
- EPS
- TOYO 1.09
- VTYX N/A
- Revenue
- TOYO $176,957,128.00
- VTYX N/A
- Revenue This Year
- TOYO N/A
- VTYX N/A
- Revenue Next Year
- TOYO N/A
- VTYX N/A
- P/E Ratio
- TOYO $3.25
- VTYX N/A
- Revenue Growth
- TOYO 183.69
- VTYX N/A
- 52 Week Low
- TOYO $1.36
- VTYX $0.78
- 52 Week High
- TOYO $8.34
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- VTYX 61.97
- Support Level
- TOYO N/A
- VTYX $1.68
- Resistance Level
- TOYO N/A
- VTYX $1.85
- Average True Range (ATR)
- TOYO 0.00
- VTYX 0.15
- MACD
- TOYO 0.00
- VTYX 0.04
- Stochastic Oscillator
- TOYO 0.00
- VTYX 67.05
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries, is engaged in research and development, production, and sales of solar cells. Geographically, the company generates revenue from Asia and the USA, out of which the majority of revenue is generated from Asia.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.